Patent application number | Description | Published |
20100052092 | METHOD FOR FABRICATING A SEMICONDUCTOR ON INSULATOR SUBSTRATE WITH REDUCED SECCO DEFECT DENSITY - The invention relates to a method for fabricating a semiconductor on insulator substrate, in particular a silicon on insulator substrate by providing a source substrate, providing a predetermined splitting area inside the source substrate by implanting atomic species, bonding the source substrate to a handle substrate, detaching a remainder of the source substrate from the source-handle component at the predetermined splitting area to thereby transfer a device layer of the source substrate onto the handle substrate, and thinning of the device layer. To obtain semiconductor on insulator substrates with a reduced Secco defect density of less than 100 per cm | 03-04-2010 |
20100267244 | METHOD FOR TREATING GERMANIUM SURFACES AND SOLUTIONS TO BE EMPLOYED THEREIN - The present invention concerns an improved method for treating germanium surfaces in order to reveal crystal defects. | 10-21-2010 |
20110104905 | ETCHING COMPOSITION, IN PARTICULAR FOR STRAINED OR STRESSED SILICON MATERIALS, METHOD FOR CHARACTERIZING DEFECTS ON SURFACES OF SUCH MATERIALS AND PROCESS OF TREATING SUCH SURFACES WITH THE ETCHING COMPOSITION - The present invention provides a chromium-free etching composition suitable for treating various silicon-containing surfaces, including strained silicon on insulator surfaces as well as stressed silicon surfaces. The novel and inventive etching composition in accordance with the present invention includes hydrofluoric acid, nitric acid, acetic acid and an alkali iodide, preferably potassium iodide, present in an amount of 1 mmol/100 ml or more. | 05-05-2011 |
Patent application number | Description | Published |
20100153076 | IMPLANT PLANNING USING AREAS REPRESENTING CARTILAGE - Described are computer-based methods and apparatuses, including computer program products, for implant planning using areas representing cartilage. A predetermined number of control points for generating a predetermined number of areas representing cartilage are determined, wherein the predetermined number of control points are based on an implant component. Measurements corresponding to a plurality of measured cartilage points are received, wherein each cartilage point is based on an associated control point from the predetermined number of control points. A plurality of areas representing cartilage are generated, wherein each area representing cartilage is larger than and projects to an associated control point from the plurality of control points. A representation of the implant component is positioned based on a representation of a bone, the representation of the bone comprising representations of the plurality of areas representing cartilage. | 06-17-2010 |
20100153081 | IMPLANT PLANNING FOR MULTIPLE IMPLANT COMPONENTS USING CONSTRAINTS - Described are computer-based methods and apparatuses, including computer program products, for implant planning for multiple implant components using constraints. A representation of a bone and a representation of a first implant component are displayed with respect to the representation of the bone. A representation of a second implant component is displayed, wherein the first implant component and the second implant component are physically separated and not connected to each other. A positioning of the representation of the second implant component that violates at least one positioning constraint is prevented, wherein the positioning constraint is based on the representation of the first implant component. | 06-17-2010 |
20120310617 | Implant Planning for Multiple Implant Components Using Constraints - Described are computer-based methods and apparatuses, including computer program products, for implant planning for multiple implant components using constraints. A representation of a bone and a representation of a first implant component are displayed with respect to the representation of the bone. A representation of a second implant component is displayed, wherein the first implant component and the second implant component are physically separated and not connected to each other. A positioning of the representation of the second implant component that violates at least one positioning constraint is prevented, wherein the positioning constraint is based on the representation of the first implant component. | 12-06-2012 |
Patent application number | Description | Published |
20100075146 | SIZING COMPOSITION FOR MINERAL FIBERS COMPRISING A PHENOLIC RESIN, AND RESULTING PRODUCTS - The present invention relates to a sizing composition for mineral fibers comprising a phenolic resin, urea, a crosslinking catalyst, and optionally additives, characterized in that the crosslinking catalyst is a mixture of ammonium sulfamate and ammonium sulfate. | 03-25-2010 |
20100158774 | TEXTURED PARTICULATE FILTER FOR CATALYTIC APPLICATIONS - Catalytic filter comprising a porous matrix consisting of an inorganic material, in the form of grains that are interconnected so as to provide cavities between them, such that the open porosity is between 30 and 60% and the median pore diameter is between 5 and 40 μm, said filter being characterized in that the grains and possibly the grain boundaries of the inorganic material are covered over at least part of their surface with a texturizing material, said texturizing consisting of irregularities having dimensions of between 10 nm and 5 microns and in that a catalytic coating at least partially coats the texturizing material and optionally, at least partially, the grains of the inorganic material. | 06-24-2010 |
20120107500 | BIOCIDAL ROOFING GRANULES, ROOFING PRODUCTS INCLUDING SUCH GRANULES, AND PROCESS FOR PREPARING SAME - Biocidal roofing granules are prepared by providing a mineral core and at least one biocidal photocatalytic metal oxide. A gel-forming inorganic coating medium is prepared and used to coat the mineral core to form a coating layer having a porous network on the mineral core, and the at least one biocidal photocatalytic metal oxide is disposed in the porous network. | 05-03-2012 |
20130252001 | LAMINATED GLASS PANEL FOR HEAD-UP DISPLAY SYSTEM - The present invention relates to a laminated glazing for information display, of the automobile windshield or architectural glazing type, comprising an assembly of at least two transparent sheets of inorganic glass or of a strong organic material, joined together by an interlayer of a thermoformable material or by multilayer foils incorporating such an interlayer, said glazing being characterized in that a luminophore material of the hydroxyterephthalate type, combined with an antioxidant additive, is integrated into said interlayer, allowing said display. | 09-26-2013 |
Patent application number | Description | Published |
20120085071 | METHOD OF TREATING AT LEAST ONE CONTAINER IN A CONTAINER TREATMENT PLANT - A method of treating at least one container in a container treatment plant, including marking at least one container with a marking, detecting the marking of the at least one container, selecting at least one container treatment machine of a container treatment plant and/or at least one operation setting of the at least one container treatment machine of the container treatment plant based on the detected marking, and treating the at least one container based on the selection of the at least one container treatment machine and/or the at least one operation setting. | 04-12-2012 |
20120100238 | Blow Moulding Machine in a Modular Design - An apparatus for producing plastic containers includes a heating module that heats plastic preforms and a moulding module for moulding the preforms into containers. The heating module includes a first transport unit that transports the preforms during the heating and a first interface. The moulding module is downstream of the heating module in the transport direction and includes a blow moulding unit for applying a flowable medium onto the preforms for expansion thereof, a second transport unit that transports the preforms during the expansion, and a second interface. The first and second interfaces allow a mechanical connection and an electrical connection between the modules such that the moulding module may be disposed on the heating module and at least one further module integrated between the heating and moulding modules. The further module treats the preforms following the heating and prior to the moulding. | 04-26-2012 |
20120101628 | METHOD AND DEVICE FOR ASSEMBLING A HANDLING UNIT OF FILLED CONTAINERS - A method for assembling a handling unit of filled containers and a corresponding method, where the handling unit comprises different container types being different with respect to at least the height, base area, base area shape or the mechanical load capacity of the containers, and the supplied containers are arranged on a handling unit carrier. The arrangement of the containers with respect to the number and/or the position and/or the rotational position of the containers on the handling unit carrier is made in dependence on at least one of the above container parameters, and the handling units can be produced flexibly and with a high packing density. | 04-26-2012 |
Patent application number | Description | Published |
20080244694 | Automated collection of forensic evidence associated with a network security incident - An automated collection of forensic evidence associated with a security incident is provided by an arrangement in which different security products called endpoints in an enterprise network are enabled for sharing security-related information over a common communication channel using an abstraction called a security assessment. A security assessment is generally configured to indicate an endpoint's understanding of a detected security incident that pertains to an object in the environment which may include users, computers, IP addresses, and website URIs (Universal Resource Identifiers). The security assessment is published by the endpoint into the channel and received by subscribing endpoints. The security assessment triggers the receiving endpoints to go into a more comprehensive or detailed mode of evidence collection. In addition, any forensic evidence having relevance to the security incident that may have already been collected prior to the detection will be marked for retention so that it is not otherwise deleted. | 10-02-2008 |
20080244742 | Detecting adversaries by correlating detected malware with web access logs - An automated arrangement for detecting adversaries is provided by examining a log that contains records of communications into and out of the enterprise network upon the detection of a security incident by which a host computer on an enterprise network becomes compromised. The log is analyzed over a window of time starting before the occurrence of the detected security incident to identify the web site URIs (Uniform Resource Identifiers) and IP (Internet Protocol) addresses (collectively “resources”) that were respectively accessed by the compromised host and/or from which traffic was received by the compromised host. When other host computers in the enterprise are detected as being compromised, a similar analysis is performed and the results of all the analyses are correlated to identify one or more resources that are common to the logged communications of all the compromised machines. | 10-02-2008 |
20080244748 | Detecting compromised computers by correlating reputation data with web access logs - Compromised host computers in an enterprise network environment comprising a plurality of security products called endpoints are detected in an automated manner by an arrangement in which a reputation service provides updates to identify resources including website URIs (Universal Resource Identifiers) and IP addresses (collectively “resources”) whose reputations have changed and represent potential threats or adversaries to the enterprise network. Responsively to the updates, a malware analyzer, which can be configured as a standalone endpoint, or incorporated into an endpoint having anti-virus/malware detection capability, or incorporated into the reputation service, will analyze logs maintained by another endpoint (typically a firewall, router, proxy server, or gateway) to identify, in a retroactive manner over some predetermined time window, those client computers in the environment that had any past communications with a resource that is newly categorized by the reputation service as malicious. Every client computer so identified is likely to be compromised. | 10-02-2008 |
Patent application number | Description | Published |
20080254089 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment. | 10-16-2008 |
20090099232 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 04-16-2009 |
20110212141 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 09-01-2011 |
20120027818 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment. | 02-02-2012 |
20120156264 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 06-21-2012 |
20130012542 | INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE - An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation. | 01-10-2013 |
Patent application number | Description | Published |
20110059076 | HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. | 03-10-2011 |
20120003221 | HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. | 01-05-2012 |
20140056898 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab. | 02-27-2014 |
20140079703 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof; and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof. | 03-20-2014 |
Patent application number | Description | Published |
20100146650 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 06-10-2010 |
20110020218 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 01-27-2011 |
20110287451 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 11-24-2011 |
20110294156 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 12-01-2011 |
20120149031 | ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 06-14-2012 |
20130028835 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 01-31-2013 |
20130031647 | HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered. | 01-31-2013 |
20130102494 | NOVEL ANTIBODY FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER - The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers. | 04-25-2013 |
20140050661 | NOVEL ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 02-20-2014 |
20140170677 | USE OF THE ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCER - The present invention relates to the use of a novel, isolated anti-CXCR4 antibody in the diagnosis of cancer. In particular, methods for diagnosing and/or prognosing an oncogenic disorder associated with CXCR4 expression, are disclosed. | 06-19-2014 |
20140170681 | NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER - The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric CXCR4, but not heterodimeric CXCR4 | 06-19-2014 |
Patent application number | Description | Published |
20080298921 | COATED CUTTING TOOL INSERT - A coated cutting tool insert is disclosed particularly useful for dry and wet machining, preferably milling, in un-, low- and high alloyed steels and cast iron, with or without raw surface zones. The insert is characterized by a WC—TaC—NbC—Co cemented carbide with a W alloyed Co-binder phase and a coating including an innermost layer of TiC | 12-04-2008 |
20080314200 | FINE GRAINED CEMENTED CARBIDE WITH REFINED STRUCTURE - The present invention relates to a fine grained WC-Co cemented carbide. By adding an extremely small amount of Ti, V, Zr, Ta or Nb alone or in combinations, a grain refined cemented carbide structure with less abnormal WC-grains has been obtained. | 12-25-2008 |
20090011267 | Sintered Cemented Carbides Using Vanadium as Gradient Former - The present invention relates to a cutting tool insert for turning consisting of a cemented carbide substrate and a coating. The cemented carbide substrate comprises WC, binder phase, and vanadium containing cubic carbide phase with a binder phase enriched surface zone essentially free of cubic carbide phase. The thermal properties of the vanadium-containing cubic phase, has turned out to give excellent resistance to thermal cracking of the insert. | 01-08-2009 |
20090242824 | CEMENTED CARBIDE WITH REFINED STRUCTURE - The present invention relates to a WC—Co cemented carbide alloy. By adding an extremely small amount of Ti, V, Zr, Ta or Nb or a combination of these, a grain refined cemented carbide structure with less abnormal WC-grains has been obtained. | 10-01-2009 |
20110183832 | FINE GRAINED CEMENTED CARBIDE WITH REFINED STRUCTURE - The present invention relates to a fine grained WC-Co cemented carbide. By adding an extremely small amount of Ti, V, Zr, Ta or Nb alone or in combinations, a grain refined cemented carbide structure with less abnormal WC-grains has been obtained. | 07-28-2011 |
Patent application number | Description | Published |
20110320437 | Infinite Browse - An online article is enhanced by displaying, in association with the article, supplemental content that includes entities that are extracted from the article and/or entities that are related to entities that are extracted from the article. The supplemental content further includes information about each of the entities. The information about an entity may be obtained by searching for the entity in one or more searchable repositories of data. For example, the supplemental content may include, for each entity, video, image, web, and/or news search results. The supplemental content may further include information such as stock quotes, abstracts, maps, scores, and so on. The entities are selected using a variety of analyses and ranking techniques based on contextual factors such as user-specific information, time-sensitive popularity trends, grammatical features, search result quality, and so on. The entities may further be selected for purposes such as generating ad-based revenue. | 12-29-2011 |
20140143243 | INFINITE BROWSE - An online article is enhanced by displaying, in association with the article, supplemental content that includes entities that are extracted from the article and/or entities that are related to entities that are extracted from the article. The supplemental content further includes information about each of the entities. The information about an entity may be obtained by searching for the entity in one or more searchable repositories of data. For example, the supplemental content may include, for each entity, video, image, web, and/or news search results. The supplemental content may further include information such as stock quotes, abstracts, maps, scores, and so on. The entities are selected using a variety of analyses and ranking techniques based on contextual factors such as user-specific information, time-sensitive popularity trends, grammatical features, search result quality, and so on. The entities may further be selected for purposes such as generating ad-based revenue. | 05-22-2014 |
Patent application number | Description | Published |
20120060857 | COMPOSITION FOR THE PERMANENT SHAPING OF HUMAN HAIR - The present invention concerns a composition for the permanent shaping of human hair based on at least one reducing agent and further comprising a cationic polymer consisting of a copolymer of vinylpyrrolidone and vinylimidazole and a homopolymer of dimethyl diallyl ammonium chloride and process for permanent shaping human hair with the said compositions. | 03-15-2012 |
20120204358 | COLOURING COMPOSITION - The present invention is related to an aqueous oxidative colouring composition for keratin fibres especially human hair. The inventors of the present invention have surprisingly found out that a composition comprising at least one oxidative dye precursor and optionally at least one coupling agent and at least one dipeptide colours hair excellently homogeneously especially hair with various level of damages and improves hair shine, combability and manageability and especially hair coloured with such composition has less flyaways. | 08-16-2012 |
20130167863 | AQUEOUS COLOURING COMPOSITION - The present invention is related to an aqueous oxidative colouring composition for keratin fibres, especially human hair. The present invention is on an aqueous composition for colouring keratin fibres especially human hair comprising at least one hair dye, at least one oxidizing agent and at least one dispersed particles of a water insoluble polymer. Furthermore, the present invention is on a two part aqueous dyeing composition, wherein the two parts are mixed prior to application onto keratin fibres especially human hair wherein the aqueous first part comprises at least one hair dye and the aqueous second part comprises at least one oxidizing agent and at least one dispersed particles of a water insoluble polymer. | 07-04-2013 |
20130251662 | COMPOSITION FOR THE PERMANENT SHAPING OF HUMAN HAIR - The present invention concerns a composition for the permanent shaping of human hair based on at least one reducing agent and further comprising a first cationic polymer consisting of a copolymer of vinylpyrrolidone and vinylimidazole and a homopolymer of dimethyl diallyl ammonium chloride and a second cationicpolymer selected from urea copolymers and process for permanent shaping human hair with the said compositions. | 09-26-2013 |
20130298936 | HAIR COLOURING COMPOSITION - Present invention relates to a dyeing composition for hair with improved dyeing and conditioning properties of hair. The object of the present invention a composition for dyeing hair based on at least one hair dye and comprising at least one amino acid surfactant and at least one natural oil. | 11-14-2013 |
20140044665 | COMPOSITION FOR KERATIN FIBERS - Present invention relates to a composition for keratin fibers especially for human hair comprising glycylglycine and/or its derivatives, an aromatic sulphonic acid and/or its salts and an anionic polymer for improving cosmetic properties of hair such as volume, body, elasticity and curl retention. | 02-13-2014 |
Patent application number | Description | Published |
20100105895 | METHOD FOR THE PRODUCTION OF HIGH-PURITY 4A, 5, 9, 10, 11, 12,-HEXAHYDRO-6H-BENZOFURO [3A, 3, 2-EF] [2] BENZAZEPINE, AND THE DERIVATIVES THEREOF - A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, whereby a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. The working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides, is essential to the process, so that the palladium catalyst is converted into an insoluble form, a form that can be easily separated. The further reaction is carried out by reduction of enantiomerically pure narwedine to form enantiomerically pure galanthamine, whereby it is then alkylated or dealkylated, so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that the direct use as a pharmaceutical raw material is made possible. | 04-29-2010 |
Patent application number | Description | Published |
20100179105 | KERATIN MATERIALS MAKE-UP KIT COMPRISING REACTIVE SILICONE COMPOUNDS AND A COMPATIBLE OIL - The invention provides a make-up kit comprising at least two compositions which are packaged separately, —the kit comprising at least one compound X, at least one compound Y and at least one catalyst or one peroxide, at least one of the compounds, X or Y, being a silicone compound, —with the proviso that the compounds X and Y—and the catalyst are not simultaneously in one of said compositions, —said compounds X and Y being able to react together by a hydrosilylation reaction or by a condensation reaction, when they are brought into contact with one another, —one at least of the first and second compositions comprising at least one compatible oil, —said compounds X and Y and said compatible oil, and their respective amounts, being such that the transfer index of a deposit comprising the two compositions is less than or equal to 40 out of 100. Finally, the invention relates to a method of making-up keratin materials that involves applying the compounds X and Y and the compatible oil. | 07-15-2010 |
20130295031 | COSMETIC COMPOSITION AND PROCESS FOR CURLING KERATIN FIBRES - The present invention relates to a cosmetic composition for coating keratin fibres, and especially the eyelashes, comprising: a polymer, derived from the (co-) (homo-)polymerization of (poly)cyclic monomers with a glass transition temperature (Tg) of greater than or equal to 80° C. and a weight-average molecular mass (Mw) of greater than 80 000 g/mol, the said (poly)cyclic monomers comprising (meth)acrylate monomers of formula H | 11-07-2013 |
Patent application number | Description | Published |
20100004443 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS - The present invention relates to linear pyridazine compounds, and more particularly to those of these compounds which are oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to pyrroles and to the uses of the pyrrole, pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the applications in the materials, environmental, electronics and optics field. | 01-07-2010 |
20100298562 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses - The present invention relates to nonlinear oligopyridazine compounds, to processes for obtaining them, to their uses, and also to their reduction to oligopyrroles and to the uses of the pyridazinylpyrrole and oligopyrrole compounds obtained. The invention relates in particular to the uses as medicaments, in particular for treating pathologies such as cancer, bacterial infections or parasitic infections, and also the uses in the materials, environmental, electronics and optics field. | 11-25-2010 |
Patent application number | Description | Published |
20090203621 | Tripeptides that Down Regulate the Activity of Plasma Membrane transporters Including Sodium-D-Glucose Cotransporter Sglt1 - The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least the amino acid sequence Q-C-P (Glutamine-Cysteine-Proline) or derivatives thereof. Furthermore, the present invention relates to a method for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, said method comprising administering to a patient in need of such amelioration, prevention and/or treatment a pharmaceutically active amount of a regulatory protein RS1 fragment or a nucleic acid molecule encoding a regulatory protein RS1 fragment, wherein said RS1 fragment is characterized in comprising at least the amino acid sequence Q-C-P (Glutamine-Cysteine-Proline) or derivatives thereof. Moreover, the present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of food and/or food supplements. | 08-13-2009 |
20120148673 | PEPTIDES THAT DOWN REGULATE THE ACTIVITY OF PLASMA MEMBRANE TRANSPORTERS INCLUDING SODIUM-D-GLUCOSE COTRANSPORTER SGLT1 - The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof. Furthermore, the present invention relates to a method for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, said method comprising administering to a patient in need of such amelioration, prevention and/or treatment a pharmaceutically active amount of said regulatory protein RS1 fragment as defined herein or a nucleic acid molecule encoding said regulatory protein RS1 fragment. Moreover, the present invention relates to the use of said regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of food, feed and/or food supplements. | 06-14-2012 |
Patent application number | Description | Published |
20100003225 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 01-07-2010 |
20110142814 | Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy - The present invention provides methods for reducing tumor necrosis factor activation of regulatory T cells (Tregs), restoring the activity of defective Tregs, and enhancing the function of Tregs using Protein Kinase C theta (PKC-θ) inhibitors. The enhancement in Treg function is of use in facilitating adoptive immunotherapy in the treatment of immunological disorders. | 06-16-2011 |
20120196919 | EX-VIVO TREATMENT OF IMMUNOLOGICAL DISORDERS WITH PKC-THETA INHIBITORS - Disclosed is a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis. Specifically, the invention relates to a method of treating an immunological disorder or atherosclerosis in a patient comprising treating blood from the patient, or a defined component of said blood, with an inhibitor of PKC-theta ex vivo and then re-administering the treated blood to the patient. | 08-02-2012 |
20140350078 | CONTROLLING REGULATORY T CELL FUNCTION - The present invention relates to a method of identifying candidate compounds useful as chemotherapeutics or anti-infective compounds or anti-inflammatory drugs. This method involves providing a plurality of test compounds. The plurality of test compounds are incubated with human Regulatory T (Treg) cells expressing Disc-Large Homo log 1 (Dlgh1) or in which Dlgh1 is suppressed, where the Treg cells have an immunological synapse (IS). Test compounds which inhibit Dlgh1 expression, recruitment to the IS, and/or activity in the Treg cells are identified as candidate compounds potentially useful as chemotherapeutics or anti-infective compounds. Test compounds which enhance Dlgh1 recruitment to the IS and/or activity in the Treg cells are identified as candidate compounds potentially useful as anti-inflammatory drugs. The present invention also relates to methods of treating inflammatory conditions, cancers, and infectious diseases in a subject, as well as methods of inhibiting Treg cell activity. | 11-27-2014 |